NASDAQ:BTX - BioTime Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.08 +0.02 (+1.89 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$1.08
Today's Range$1.0450 - $1.11
52-Week Range$0.66 - $2.81
Volume258,617 shs
Average Volume860,922 shs
Market Capitalization$161.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTX
CUSIPN/A
CIKN/A
Phone510-521-3390

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$161.61 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

BioTime (NASDAQ:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the NASDAQ under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NASDAQ:BTX) issued its quarterly earnings data on Thursday, May, 9th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.36. The firm had revenue of $0.93 million for the quarter, compared to the consensus estimate of $0.66 million. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for BioTime.

What is the consensus analysts' recommendation for BioTime?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.

Has BioTime been receiving favorable news coverage?

News stories about BTX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioTime earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of BioTime's key competitors?

What other stocks do shareholders of BioTime own?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
  • Mr. Brian M. Culley, CEO , Pres & Director (Age 48)
  • Ms. Brandi L. Roberts, CFO & Sr. VP of Fin. (Age 45)

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $1.08.

How big of a company is BioTime?

BioTime has a market capitalization of $161.61 million.

What is BioTime's official website?

The official website for BioTime is http://www.biotimeinc.com/.

How can I contact BioTime?

The company can be reached via phone at 510-521-3390.


MarketBeat Community Rating for BioTime (NASDAQ BTX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  13
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel